HC Wainwright reiterated their buy rating on shares of Gritstone bio (NASDAQ:GRTS – Free Report) in a research note published on Thursday morning, Benzinga reports. They currently have a $4.00 target price on the stock.
Other equities research analysts have also recently issued reports about the company. B. Riley reissued a buy rating and set a $3.00 price target (down from $6.00) on shares of Gritstone bio in a report on Friday, May 24th. JMP Securities reiterated a market outperform rating and set a $5.00 target price on shares of Gritstone bio in a research report on Monday, August 5th.
Check Out Our Latest Research Report on GRTS
Gritstone bio Trading Down 5.7 %
Gritstone bio (NASDAQ:GRTS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.12. The firm had revenue of $0.92 million during the quarter, compared to analysts’ expectations of $2.77 million. Gritstone bio had a negative net margin of 926.13% and a negative return on equity of 232.42%. As a group, research analysts predict that Gritstone bio will post -0.99 earnings per share for the current year.
Hedge Funds Weigh In On Gritstone bio
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 DIFC Ltd bought a new position in shares of Gritstone bio during the 2nd quarter valued at about $29,000. Tidal Investments LLC bought a new position in shares of Gritstone bio during the 1st quarter valued at about $63,000. Lazard Asset Management LLC bought a new position in shares of Gritstone bio during the 1st quarter valued at about $70,000. Klingman & Associates LLC bought a new position in shares of Gritstone bio during the 1st quarter valued at about $89,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Gritstone bio during the 2nd quarter valued at about $96,000. Institutional investors own 48.46% of the company’s stock.
About Gritstone bio
Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.
Further Reading
- Five stocks we like better than Gritstone bio
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 8/12 – 8/16
- Are Penny Stocks a Good Fit for Your Portfolio?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Gritstone bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone bio and related companies with MarketBeat.com's FREE daily email newsletter.